Novo Nordisk (NVO.N) chief scientific officer said next-generation GLP-1 may
offer differentiated advantages in efficacy, convenience, safety and
tolerability.
2026-09-21
Novo Nordisk (NVO.N) chief scientific officer said next-generation GLP-1 may
offer differentiated advantages in efficacy, convenience, safety and
tolerability.